$Cognition Therapeutics (CGTX.US)$ NEWS Cognition Therapeuti...
NEWS
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent research showing Aβ oligomers binding to synapses in Alzheimer's patients and how CT1812 can reverse this binding and reduce toxicity. Highlights include the use of quantitative EEG as a biomarker in the Phase 2 ‘SEQUEL’ study, which showed improvements in synaptic function and brain connectivity after four weeks of CT1812 treatment. Dr. Hamby presented proteomic analysis results demonstrating CT1812's positive effects on proteins and pathways linked to Alzheimer's. The discussion was moderated by Dr. Anthony Caggiano, featuring Dr. Mary Hamby, Dr. Everard Vijverberg, and Dr. Tara Spires-Jones.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
835Followers
62Following
5555Visitors
Follow